KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Gains from Investment Securities (2018 - 2025)

Moderna (MRNA) has disclosed Gains from Investment Securities for 8 consecutive years, with -$27.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities rose 78.74% to -$27.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$77.0 million, a 48.08% decrease, with the full-year FY2025 number at -$77.0 million, down 48.08% from a year prior.
  • Gains from Investment Securities was -$27.0 million for Q4 2025 at Moderna, down from -$14.0 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $2.8 billion in Q4 2022 to a low of -$130.0 million in Q3 2022.
  • A 5-year average of $162.1 million and a median of -$8.0 million in 2025 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: surged 4600.0% in 2022, then plummeted 805.56% in 2024.
  • Moderna's Gains from Investment Securities stood at -$62.0 million in 2021, then surged by 4559.68% to $2.8 billion in 2022, then crashed by 99.35% to $18.0 million in 2023, then tumbled by 805.56% to -$127.0 million in 2024, then soared by 78.74% to -$27.0 million in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Gains from Investment Securities are -$27.0 million (Q4 2025), -$14.0 million (Q3 2025), and -$34.0 million (Q2 2025).